| Literature DB >> 25309510 |
Miguel Angel Fernández-Del-Olmo1, Jose Andres Sanchez1, Olalla Bello2, Virginia Lopez-Alonso1, Gonzalo Márquez1, Luis Morenilla1, Xabier Castro1, Manolo Giraldez1, Diego Santos-García3.
Abstract
Gait disturbances are one of the principal and most incapacitating symptoms of Parkinson's disease (PD). In addition, walking economy is impaired in PD patients and could contribute to excess fatigue in this population. An important number of studies have shown that treadmill training can improve kinematic parameters in PD patients. However, the effects of treadmill and overground walking on the walking economy remain unknown. The goal of this study was to explore the walking economy changes in response to a treadmill and an overground training program, as well as the differences in the walking economy during treadmill and overground walking. Twenty-two mild PD patients were randomly assigned to a treadmill or overground training group. The training program consisted of 5 weeks (3 sessions/week). We evaluated the energy expenditure of overground walking, before and after each of the training programs. The energy expenditure of treadmill walking (before the program) was also evaluated. The treadmill, but not the overground training program, lead to an improvement in the walking economy (the rate of oxygen consumed per distance during overground walking at a preferred speed) in PD patients. In addition, walking on a treadmill required more energy expenditure compared with overground walking at the same speed. This study provides evidence that in mild PD patients, treadmill training is more beneficial compared with that of walking overground, leading to a greater improvement in the walking economy. This finding is of clinical importance for the therapeutic administration of exercise in PD.Entities:
Keywords: Parkinson’s disease; exercise; gait; treadmill; walking economy
Year: 2014 PMID: 25309510 PMCID: PMC4176037 DOI: 10.3389/fneur.2014.00191
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Details of Parkinson’s disease patient characteristics.
| Patient number | Age (years) | Sex | Height (m) | Disease duration (years) | Type | H&Y | UPDRS motor | Medication per day (mg) |
|---|---|---|---|---|---|---|---|---|
| 1 | 66 | F | 1.60 | 12 | T | 2.5 | 12 | Levodopa/carbidopa 200/50, levodopa/benserazide 550/137.5, rotigotine 6, rasagiline 1, amantadine 200 |
| 2 | 79 | F | 1.49 | 7 | AR | 3 | 35 | Levodopa/carbidopa 400/50, pramipexole 0.18 |
| 3 | 58 | M | 1.76 | 6 | M | 2 | 23 | Levodopa/carbidopa 500/125, rasagiline 1, rotigotine 4 |
| 4 | 60 | M | 1.69 | 6 | AR | 2 | 12 | Levodopa/carbidopa 800/200, entacapone 800, pramipexole 3.15 |
| 5 | 60 | M | 1.68 | 7 | M | 2 | 13 | Levodopa/carbidopa 500/125, ropinirole 12, trihexyphenidyl 2 |
| 6 | 62 | F | 1.59 | 2 | AR | 3 | 31 | Levodopa/carbidopa 600/150, entacapone 600, rotigotine 6, pramipexole 3.15 |
| 7 | 68 | M | 1.65 | 1 | AR | 2.5 | 16 | Levodopa/carbidopa 150/37.5, entacapone 600, rasagiline 1 |
| 8 | 50 | M | 1.70 | 5 | AR | 2 | 19 | Levodopa/carbidopa 300/75, rasagiline 1, rotigotine 8 |
| 9 | 67 | M | 1.80 | 3 | M | 2 | 15 | Levodopa/benserazide 500/125, rasagiline 1, pramipexole 2.64 |
| 10 | 39 | F | 1.63 | 1 | T | 2 | 18 | Levodopa/carbidopa 375/93.75, entacapone 600, rasagiline 1 |
| 11 | 45 | M | 1.74 | 3 | M | 2 | 11 | Levodopa/carbidopa 225/56.25, entacapone 600, rasagiline 1, rotigotine 4 |
| Mean | 59.45 | 1.66 | 4.82 | 2.27 | 18.64 | |||
| SD | 11.32 | 0.08 | 3.28 | 0.41 | 7.99 | |||
| 1 | 55 | M | 1.72 | 6 | M | 2 | 23 | Levodopa/carbidopa 225/56.25, entacapone 600, rasagiline 1, ropinirole 20 |
| 2 | 56 | M | 1.65 | 2 | AR | 1.5 | 12 | Pramipexole 2.1 |
| 3 | 51 | F | 1.68 | 5 | AR | 2 | 36 | Levodopa/benserazide 600/150 |
| 4 | 46 | F | 1.61 | 6 | M | 2.5 | 23 | Levodopa/carbidopa 150/37.5, entacapone 600, rasagiline 1 |
| 5 | 46 | F | 1.62 | 1 | AR | 2 | 23 | Levodopa/carbidopa 150/37.5, rasagiline 1, pramipexole 3.15 |
| 6 | 62 | M | 1.73 | 4 | AR | 2 | 12 | Levodopa/carbidopa 150/37.5, entacapone 600, pramipexole 3.15 |
| 7 | 61 | F | 1.57 | 6 | M | 2 | 23 | Levodopa/carbidopa 500/50, pramipexole 3.15 |
| 8 | 63 | M | 1.74 | 8 | AR | 2 | 21 | Levodopa/carbidopa 750/187.5, entacapone 1000, rasagiline 1, pramipexole 3.15 |
| 9 | 78 | M | 1.62 | 9 | AR | 3 | 38 | Levodopa/carbidopa 400/100, levodopa/benserazide 700/175, ropinirole 20 |
| 10 | 54 | F | 1.57 | 6 | AR | 2.5 | 25 | Levodopa/carbidopa 400/100, entacapone 800, rotigotine 12 |
| 11 | 66 | M | 1.67 | 1.5 | T | 1 | 7 | Levodopa/carbidopa 375/37.5, rasagiline 1 |
| Mean | 58.00 | 1.65 | 4.95 | 2.05 | 22.09 | |||
| SD | 9.38 | 0.06 | 2.59 | 0.52 | 9.44 | |||
| 0.74 | 0.63 | 0.91 | 0.42 | 0.36 | ||||
Figure 1Comparison of metabolic parameters for overground vs. treadmill walking. *p < 0.001; #p = 0.001.
Comparison of kinematic parameters for overground vs. treadmill walking.
| Overground | Treadmill | |||
|---|---|---|---|---|
| Speed (m/s) | 1.30 ± 0.27 | 1.30 ± 0.27 | ||
| Cadence (steps/min) | 118.28 ± 10.26 | 117 ± 12.59 | 0.43 | 0.67 |
| Stride length (m) | 1.31 ± 0.21 | 1.32 ± 0.21 | 0.60 | 0.53 |
| Stride time variability (%) | 1.84 ± 1.05 | 1.98 ± 1.08 | 0.88 | 0.38 |
| Energy expenditure (ml/kg/min) | 15.54 ± 3.24 | 19.40 ± 4.78 | 5.61 | <0.001 |
| Energy expenditure per meter (ml/kg/m) | 0.19 ± 0.04 | 0.24 ± 0.03 | 5.96 | <0.001 |
| Respiratory exchange ratio (CO2/O2 uptake) | 0.78 ± 0.05 | 0.81 ± 0.06 | 3.78 | 0.001 |
| Heart rate (pulse/min) | 103.6 ± 15.52 | 113.75 ± 17.77 | 5.57 | <0.001 |
Metabolic effects on the evaluated tasks.
| Gground | Gtreadmill | ||||
|---|---|---|---|---|---|
| T0 | T1 | T0 | T1 | ||
| Walking at preferred speed | Energy expenditure (ml/kg/min) | 14.81 ± 3.87 | 16.19 ± 4.53 | 15.62 ± 2.26 | 15.89 ± 3.07 |
| Energy expenditure per meter (ml/kg/m) | 0.18 ± 0.02 | 0.19 ± 0.031 | 0.21 ± 0.04 | 0.19 ± 0.02 | |
| Respiratory exchange ratio (CO2/O2 uptake) | 0.77 ± 0.06 | 0.78 ± 0.06 | 0.78 ± 0.05 | 0.76 ± 0.05 | |
| Heart rate (pulse/min) | 98.6 ± 18.45 | 95.59 ± 17.5 | 104.22 ± 11.79 | 104.63 ± 16.29 | |
| Walking on treadmill at initial preferred speed | Energy expenditure (ml/kg/min) | 19.12 ± 3.97 | 19.60 ± 3.36 | ||
| Energy expenditure per meter (ml/kg/m) | 0.23 ± 0.02 | 0.25 ± 0.04 | |||
| Respiratory exchange ratio (CO2/O2 uptake) | 0.80 ± 0.06 | 0.82 ± 0.07 | |||
| Heart rate (pulse/min) | 107.95 ± 18.18 | 117.04 ± 18.16 | |||
*p < 0.05.